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Abstract 
Emerging integrative analysis of genomic and anatomical imaging data which has not been well 
developed, provides invaluable information for the holistic discovery of the genomic structure of 
disease and has the potential to open a new avenue for discovering novel disease susceptibility 
genes which cannot be identified if they are analyzed separately.  A key issue to the success of 
imaging and genomic data analysis is how to reduce their dimensions. Most previous methods 
for imaging information extraction and RNA-seq data reduction do not explore imaging spatial 
information and often ignore gene expression variation at genomic positional level. To overcome 
these limitations, we extend functional principle component analysis from one dimension to two 
dimension (2DFPCA) for representing imaging data and develop a multiple functional linear 
model (MFLM) in which functional principal scores of images are taken as multiple quantitative 
traits and RNA-seq profile across a gene is taken as a function predictor for assessing the 
association of gene expression with images. The developed method has been applied to image 
and RNA-seq data of ovarian cancer and KIRC studies. We identified 24 and 84 genes whose 
expressions were associated with imaging variations in ovarian cancer and KIRC studies, 
respectively. Our results showed that many significantly associated genes with images were not 
differentially expressed, but revealed their morphological and metabolic functions. The results 
also demonstrated that the peaks of the estimated regression coefficient function in the MFLM 
often allowed the discovery of splicing sites and multiple isoform of gene expressions.  
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Significance 
Despite imaging-genetics shows great promise as a powerful tool for dissecting genomic 
structures of complex diseases; to date, very few imaging and RNA-seq analyses have been 
performed.  We present a novel model for the integrative analysis of imaging and RNA-seq data 
and offer a new paradigm for RNA-seq data analysis. The results show that imaging and RNA-
seq analysis can detect cancer susceptibility genes that are not differentially expressed. 
Surprisingly, most image associated genes display alternative splicing, which change the protein 
structures and cell morphologies. The results also demonstrate that the peaks of regression 
coefficient functions in the model were located in the splicing sites. Integrative imaging and 
RNA-seq analysis opens a new avenue for identifying disease causing genes.  
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\body 
There is increasing consensus that imaging measures show closer associations with genomic 
variants and the penetrance of an individual genomic variant is expected to be higher at the 
imaging level than at the clinical diagnostic and outcome level. Imaging measures as an 
endophenotype have a higher power to identify genomic variants that significantly contribute to 
the development of diseases (1, 2). Integrated genomic and imaging data analysis is a new 
powerful approach used to uncover the individual variability and mechanism of disease 
development (3). Both imaging and genomics generate a huge amount of data that present 
critical bottlenecks in their analysis. Despite its great success, integrative analysis of 
unprecedented high dimensional imaging and genomic data faces great conceptual and 
computational challenges (4). 
A key issue to the success of imaging and genomic data analysis is how to reduce dimensions 
of both imaging and genomic data. Previously investigated methods for imaging information 
extraction include single region-of-interest (ROI) methods, voxelwise approaches, principal 
component analysis (PCA), singular value decomposition, self-organizing Map (SOM) and 
multidimensional scaling (MDS) (5). However, these multivariate dimension reduction methods 
do not explore imaging spatial information. They take the set of spectral images as an unordered 
set of high dimensional pixels (6). Spatial information is very important for image cluster and 
classification analysis. To overcome limitations of multivariate dimension reduction and to 
utilize spatial information of the image signal, we extend the widely used one dimensional 
functional principal component analysis (FPCA) (7) to high dimensional FPCA to extract 
imaging signals.  
The traditional methods for assessing the relationship between gene expressions measured by 
microarray and phenotypes are linear regressions (8, 9). However, the rapidly developed next-
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generation sequencing (NGS) technologies have become the platform of choice for gene 
expression profiling. RNA-seq for expression profiling offers a comprehensive picture of the 
transcriptome, with less background noise and a wider dynamic range of expression (10). Unlike 
microarrays for measuring gene expression, RNA-seq provides multiple layers of resolutions and 
transcriptome complexity:  the expression at exon, SNP, and positional level, splicing, 
transcription start sites, polyadenylation sites, post-transcriptional RNA editing across the entire 
gene, and isoform and allele-specific expression (11).  The current linear regression for modeling 
association of gene expressions with phenotypes quantifies the expression level of a 
gene/transcript by a single number that summarizes all the reads mapped to that gene/transcript. 
A single number measuring gene expression level ignores gene expression variation at the 
genomic positions. Therefore, linear regression is appropriate for microarray expression data, but 
may not be good for RNA-seq data.  
To overcome these limitations, we propose a multiple functional linear model (MFLM) in 
which functional principal component scores of images are taken as multiple quantitative traits 
and RNA-seq profile across a gene is taken as a function predictor for assessing the association 
of gene expression with imaging signals which can take gene splicing and expression variation at 
genomic positional level into account.  
Results 
     To evaluate its performance, the proposed MFLM for integrative imaging and RNA-seq data 
analysis was applied to images and RNA-seq datasets of ovarian cancer (OV) and kidney renal 
clear cell carcinoma (KIRC) which were downloaded from the TCGA datasets. The ovarian 
cancer dataset consists of 231 tumor tissue samples with histology images and RNA-seq profiles 
of 16,598 genes (after quality control). The KIRC dataset consists of 188 (121 tumor and 67 
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normal tissue samples) with histology images and RNA-seq profiles of 16,775 genes (after 
quality control). RNA-seq data were created by Illumina HiSeq 2000 PE paired-end RNA 
sequencing. More detailed information can be downloaded from TCGA website 
(http://cancergenome.nih.gov/).  
FPCA for Imaging Signal Extraction 
   In our study, we compared our two dimensional FPCA with the traditional PCA by capturing 
space variation of image signals. To evaluate the performance of the two methods on image 
compression, we compared the original histology images and reconstructed images by two 
dimensional FPCA and by PCA. The result clearly demonstrated that the reconstructed images 
by FPCA were much closer to the original images than that by PCA (Fig. S1). In addition, 90.3% 
of the total imaging variation could be explained by top 30 functional principal components, 
while only 63.6% of the total imaging variation was explained by top 30 traditional principal 
components. Therefore, two dimensional FPCA is a better and more authentic image 
compression algorithm for image signal capturing than traditional PCA with minimal loss of 
information and fewer principal components usage.  
Behavior of the MFLM for Integrative Analysis of RNA-seq and Imaging Data 
     In the process of integrative analysis of RNA-seq and image data, histology image data were 
compressed with our proposed two dimensional FPCA, and the FPC scores were taken as 
phenotypes. We considered gene expression values at single-base resolution and represented the 
expression profile of a gene by a functional curve, called a “gene expression function”. We used 
the Karhunen-Loeve decomposition (7) to decompose the random gene expression function into 
orthogonal FPCs. The multiple FPC scores for imaging signal extraction were regressed on the 
FPC scores that were obtained from decomposition of the gene expression functions. In other 
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words, we proposed to use MFLM for integrative analysis of RNA-seq and imaging data 
(Materials and Methods). Two FPCs that accounted for 81.7% and 88.6% of variation of imaging 
signals for ovarian and KIRC, respectively, were selected as phenotypes. The number of selected 
FPCs for the RNA-seq which accounted for 95% of the variation of gene expression ranges from 
2 to 60.  P-values for declaring significant association after applying the Bonferroni correction 
for multiple tests in ovarian cancer and KIRC analysis were 610012.3  and 61098.2  , 
respectively. To indirectly examine the validity of  MFLM for assessing the association of gene 
expression with the histology images, we plotted a QQ plot of the test in the MFLM (Fig.1). The 
QQ plots clearly showed that the false positive rates of the MFLM for detection of the 
association of gene expression with histology images in both ovarian cancer and KIRC studies 
were controlled. 
 MFLM for Integrative Analysis of RNA-seq and Histology Images 
    Three statistical methods: MFLM with FPC scores as phenotypes, MFLM with image 
descriptors (12) as phenotypes and multivariate regression model with FPC score as phenotypes 
and a single gene expression value (level 3 in TCGA datasets) as a regressor were applied to the 
ovarian cancer and KIRC datasets. For the ovarian cancer dataset, MFLM with FPC scores as 
phenotypes, MFLM with image descriptors and multivariate regression identified 24, 2 and 0 
genes whose expressions were associated with image signals, respectively. Similarly, for the 
KIRC dataset, MFLM with FPC scores as phenotypes, MFLM with image descriptors and 
multivariate linear model (MLM) identified 84, 6 and 1 genes whose expressions were associated 
with image signals, respectively. The results were summarized in Tables 1 and 2.  
     Several remarkable features from these results were observed. First, the P-values calculated 
from the MFLM with FPC scores as phenotypes were much smaller than that calculated from the 
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MFLM with image descriptors as phenotypes. Two methods assumed the same functional linear 
model (FLM) for RNA-seq data, but with a different approach to imaging signal reduction. The 
FPCA can reduce the dimensions of the imaging data more substantially than the traditional 
image descriptors. Therefore, the degrees of the test statistic in the MFLM with FPC score as 
phenotypes were much smaller than that in the MFLM with descriptors as phenotypes, which 
lead to the smaller P-values of the tests in the MFLM with the FPC scores as phenotypes. Second, 
we observed very few significant associations of the gene expression in the MLM. The MLM 
used the same FPCA for imaging data reduction, but model the gene expression level in a gene 
as a single value. The results demonstrated that the widely used single value representation of the 
expression level in the gene overlooked the expression variation across the gene, which led to 
large P-values of the tests. Third, expressions of genes which were associated with the imaging 
signal may or may not be differentially expressed (Table S1, Fig. S2). In other words, significant 
association of gene expression with imaging signals can provide additional information which 
differential expressions cannot offer. For example, genes NOTCH1, ARHGEF11  and BRD4 that 
were associated with imaging signals, but not differentially expressed between tumor and normal 
tissues were reported to regulates interactions between physically adjacent cells and induce 
G2/M arrest and triggers apoptosis in renal cell carcinoma (13), associated with kidney injury in 
the Dahl salt-sensitive rat (14) and kidney disease (15). Fourth, the MFLM with FPC scores as 
phenotypes could identify associated genes that showed alternative splicing expression pattern.  
To illustrate this, we presented average expression of microtubule associated tumor suppressor 
1 (MTUS1) in the KIRC study (Fig. 2). So far, seven isoforms of MTUS1 have been discovered. 
We observed from Fig. 2 that a higher expression level in exon 1, exon 2 and exon 15 in the 
normal samples than that in tumor samples, and alternatively spliced transcript variations 
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encoding different isoforms between tumor and normal samples were substantial. To our surprise, 
in Fig. 2 we also observed a remarkable feature that locations of the two peaks of the regression 
coefficient function )(s were close to the splicing sites at the genomic positions 17613470 and 
17554765.  This might indicate that splicing sites affect the tissue structure variation which was 
measured by imaging signals. MTUS1 is interacted with microtubules to control cellular 
architecture and organize microtubule arrays. Express variation of MTUS1 influences variation in 
microtubule structure, which in turn causes variation of histology images. Disruption of 
microtubule-dependent processes is involved in cancer development and metastasis (16). Fifth, 
imaging data convey relatively closer association with the disease than traditional phenotypes 
(17). The genes significantly associated with imaging will have profound implication in cellular 
function and disease development. 
 In the ovarian cancer study, among the 24 significantly associated genes with histology 
images, protein tyrosine phosphatase receptor type G (PTPRG) that regulate a variety of cellular 
processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation, is a 
functional tumor suppressor gene and involved in ovarian tumorigenesis (18, 19). Cytoplasmic 
polyadenylation element binding protein 3 (CPEB3) that controls cell cycle progression, 
regulates senescence, establishes cell polarity, and promotes tumorigenesis and metastasis (20), 
plays a role in ovarian cancer development (21). In the KIRC study, integrin, alpha 9 (ITGA9) 
that participates in regulation of myotube formation (22), is reported to be involved in renal 
carcinomas (23), NOTCH1 that regulates interactions between physically adjacent cells, is 
reported to trigger apoptosis in renal cell carcinoma (24), and Rho guanine nucleotide exchange 
factor (GEF) 11 (ARHGEF11) whose expression induces the reorganization of the actin 
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cytoskeleton and the formation of membrane ruffling and filopodia, is associated with kidney 
injury (25) and key regulators of tumorigenesis (26). 
Image Associated Gene Form Protein-Protein Interaction Networks 
     A large proportion of genes whose expression variation was associated with imaging signal 
variation formed protein-protein interaction networks (Fig. 3). In the ovarian cancer study, 
proteins of 30 out of 130 significantly associated genes identified by false discovery rate are 
interacted with each other to form a network. Hub gene SETDB1, encoding a histone 
methyltransferase in the network, is an oncogene and is involved in the development of several 
cancers (27). Another hub gene Glul that catalyzes the synthesis of glutamine from glutamate 
and ammonia is involved in cell proliferation, inhibition of apoptosis, and cell signaling, plays 
key roles in several cancers (28).  We also observed from the KIRC study that proteins of 28 out 
of the 84 significantly associated genes with imaging signals are interacted to form a network, in 
which 10 genes are differentially expressed between tumor and normal tissues. A hub gene 
REV3L with 11 degrees in the network is the catalytic subunit of DNA translesion synthesis 
polymerase ζ. It involves a variety of DNA-damaging, genome stability, cytotoxicity, and 
resistance to chemotherapeutic agents. Surprisingly, although REV3L is not differentially 
expressed, it is reported to be associated with lung, breast, colon cancers and gliomas (29-31). 
The interacted genes KCNN3, ANKRD17, BRD4, NOTCH1, SMAD2, ZMIZ1, UFD1L, and 
MINK1 are associated with various cancers (32-38). Most of these genes are not differentially 
expressed, but are involved in the formation of cell and tissue structures. Their gene expression 
variations cause imaging signal variations and are thereby captured by integrative RNA-seq and 
imaging analysis.  
Image Associated Genes and Alternative Splicing 
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    We performed FPCA on RNA-seq profiles of each image associated gene and obtained their 
FPC scores in the ovarian cancer and KIRC studies. Then, we used a hierarchical algorithm to 
cluster genes based on their FPC scores. The results were shown in Fig. 4 and Fig. S3. We used 
DAVID (the Database for Annotation, Visualization and Integrated Discovery) Bioinformatics 
Resources (39), to extract biological features/meaning.  DAVID bioinformatics gene function 
annotation analysis showed that most image associated genes play important roles in alternative 
splicing (Fig. 2 and Fig. S2). We observed that the genes with the similar patterns of alternative 
splicing sites are grouped together (Fig. S4). There is increasing consensus that alternative 
splicing may affect large and conservative regions of the protein structures and often leads to 
changes in cell morphologies and phenotypes such as actin cytoskeleton remodeling, regulation 
of cell-cell junction formation and regulation of cell migrations (40, 41). Variations in alternative 
splicing of gene expression lead to variations in cell morphologies and phenotypes, thus 
influencing variations of imaging measures of the cells. This opens a new pathway to cancer 
development and progression.  
 
Discussion 
    The current major focus on RNA-seq data analysis is to identify differentially expressed genes 
(42) and major paradigm of RNA-seq data analysis is to test differences in gene expression level 
that is measured by a single value of summarizing statistic. However, there is increasingly 
recognition that the differential expression feature of genes may not be a unique source to cause 
disease.  Changes in cell morphologies and motility can also influence development and 
progression of diseases. In this paper we have presented a MFLM with FPC scores of imaging 
measures as phenotypes for the integrative analysis of imaging and RNA-seq data and offered a 
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new alternative paradigm for RNA-seq data analysis. We have also shifted the paradigm of 
RNA-seq data analysis from the single value representation of gene expression to the random 
function representation of RNA-seq profile which takes gene expression variation at the genomic 
positional level into account. Our study has made several remarkable findings. 
The first finding is that imaging and RNA-seq analysis can detect cancer susceptibility genes 
that are not differentially expressed. Changes in cell morphologies, motility and phenotypes play 
important roles in the development and progression of the cancer.  Genes causing these changes 
may not be differentially expressed between tumor and normal tissue samples and hence cannot 
be detected by gene differential expression analysis. The integrative analysis of imaging and 
RNA-seq data opens a new avenue for identifying cancer causing genes. 
The second finding is that the function feature of image associated genes is alternative splicing. 
Surprisingly, we found that the peaks of regression coefficient functions in the MFLM of 
imaging and RNA-seq data analysis were located in the splicing sites. Alternative splicing often 
changes the protein structures, cell morphologies and phenotypes (40, 41). These changes 
generate variation of histology images of tumor tissues, which in turn provide information for 
discovery of image associated genes. 
The third finding is that the widely used single value representation of the expression level in 
the gene overlooks the expression variation at the genomic positional level across the gene and 
hence has great limitations to identify image associated genes.  
As demonstrated in the real data analysis, the MFLM showed great promise as a tool for 
integrative analysis of imaging and RNA-seq data.  However, to date, very few integrative 
analyses of imaging and RNA-seq data have been performed.  The results presented in this paper 
are among the first such studies and hence are considered preliminary. The number of selected 
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orthogonal basis functions in the expansion of RNA-seq function will influence the performance 
of the integrative analysis of imaging and RNA-seq data.  Genome-wide imaging and RNA-seq 
data analysis still poses great challenges. The main purpose of this paper is to stimulate 
discussion on the optimal strategies for genome-wide imaging and RNA-seq data analysis.  
Methods 
Two dimensional functional principal component analysis 
One dimensional functional principal component analysis (FPCA) has been well developed (7). 
Now we extend one dimensional FPCA to two dimensional FPCA.  Consider a two dimensional 
region. Let s and t denote coordinates in the s axis and t  axis, respectively. Let ),( tsx  be a 
centered image signal located at s and t  of the region. The signal ),( tsx  is a function of 
locations s and t .  
Consider a linear combination of functional values: 
 
S T
dsdttsxtsf ),(),( , 
where ),( ts  is a weight function. To capture the variations in the random functions, we chose 
weight function ),( ts  to maximize the variance of f , which, after  imposing a constraint to 
make the solution unique, leads to the following optimization problem: 
 
.1),(          s.t.
),(),,,(),( max       
2
221122221111
 
   
dsdtts
tdsdtsdtststsRts
S T
S T S T


    [1] 
where )),(),,(cov(),,,( 22112211 tsxtsxtstsR  is the covariance function of the image signal 
function ),( tsx . By variation calculus (43), we obtain the eigenequation as a solution to the 
optimization problem (1): 
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JjtsdtdstststsR jj ,...,2,1),,(),(),,,( 11
S T
22222211       [2] 
for an appropriate eigenvalue  , where ),( tsj is an eigenfunction. The random functions 
),( tsxi can be expanded in terms of eigenfunctions as 



K
j
jiji Nitsstx
1
,,...,1),,(),(         [3] 
where    
S T
jiij dsdttsstx .),(),( , JjNi ,...,1,,...,1  are FPC scores (Supplementary note 1). 
Multivariate Functional Linear Model for Integrative Analysis of Imaging and RNA-seq 
Data 
     We take K FPC scores as K  quantitative traits. Assume that n individuals are sampled. Let 
,,...,2,1, Kkyik  be K trait values of the i -th individual. Consider a genomic region [a, b]. Let 
 )(txi be a RNA-seq profile, the number of reads as a function of the genomic position ,t  of the 
i-th individual defined in the regions [a, b]. The multivariate functional linear model (MFLM) 
for integrative analysis of imaging and RNA-seq data can be defined as 
,)()(0  
T
ikikkik dttxty  [4]   
where k0 is an overall mean,  )(tk  are a regression coefficient function for the k -th trait, 
Kk ,...,1  , ik  are independent and identically distributed normal variables with mean of zero 
and covariance matrix  .  
    We assume that both trait values and RNA-seq profiles are centered. The RNA-seq profiles 
 )(txi are expanded in terms of the orthonormal basis function as: 



J
j
jiji ttx
1
)()(  ,         [5] 
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where )(tj are sequences of the orthonormal basis functions. Substituting equation (5) into 
equation (4), we obtain 
,,...,1,,...,1,
1
Kkniy ik
J
j
kjijik 

       [6] 
where   
T
jkkj dttt )()( . The parameters kj are referred to as genetic additive  effect scores 
for the k -th trait.  
Equation (6) can be rewritten in a matrix form: 
 Y . 
The standard least square estimators of   and the variance covariance matrix   are given by 
)()(ˆ 1 YYTT   ,         
)ˆ()ˆ(
1ˆ  YY
n
T .        
Denote the matrix 
TT  1)( by A . Then, the estimator of the parameter  is given by 
)(ˆ YYA  .  
The variance-covariance matrix of the estimator of the parameter   is given by 
 
)(
))()(())ˆ(var(
T
T
knk
AA
AIIAIvec

 
    [7] 
    An essential problem in the QTL analysis or in the integrative analysis of imaging and RNA-
seq data is to test the association of a gene with imaging phenotype. Formally, we investigate the 
problem of testing the following hypothesis: 
16 
 
,,...,1],,[,0)( Kkbattk   
which is equivalent to testing the hypothesis: 
0:0 H . 
Define the test statistic for testing the association of a gene with K  quantitative traits as 
)ˆ()ˆ( 1  vecvecT T  . [8] 
Let )(rank r . 
Then, under the null hypothesis  0:0 H , T is asymptotically distributed as a central 
2
)(KJ or 
2
)(r distribution if J components are taken in the expansion equation (5) (Supplementary note 2). 
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Figure Legends 
Fig. 1. 
A. QQ plot for the KIRC dataset. 
B. QQ plot for the  ovarian cancer dataset. 
Fig. 2. 
A. Number of reads as a function of the genomic position of gene MTUS1. 
B. Regression coefficient function of gene MTUS1 in the MFLM. 
Fig. 3. 
A. Proteins of 30 out of 130 significantly associated genes identified by false discovery rate are 
interacted with each other to form a network in the ovarian cancer study where genes in yellow 
color were differentially expressed between tumor and normal tissues and dotted vertical lines 
denote location of splicing sites. 
B. Proteins of 28 out of 84 significantly associated genes are interacted each other to form a 
network in the KIRC study. 
Fig. 4. Clusters of image associated genes in the ovarian cancer study by k -means clustering 
algorithms. 
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Supplementary Figures 
Fig, S1. 
A. Original ovarian cancer histology image. 
B. Reconstruction of the ovarian cancer histology images from 30 FPC scores (explain 90.3% of 
the variations). 
C. Reconstruction of the ovarian cancer histology images from 30 PC scores (explain 63.6% of 
the variations). 
D. Original KIRC histology image.  
E. Reconstruction of the kidney cancer histology image from 30 FPC scores (explain 93.6% of 
the variations).  
F. Reconstruction of the kidney cancer histology images from 30 PC scores (explain 57.4% of 
the variations). 
Fig. S2. RNA-Seq profiles and splicing sites of 33 genes that were associated with images, but 
not differentially expressed between tumor and normal tissue samples in the KIRC study, where 
dotted vertical lines denote location of splicing sites. 
Fig. S3.  Clusters of image associated genes in the KIRC study by k -means clustering 
algorithms.  
Fig. S4. 
A. Four genes TTC23, CPEB3, CAPN14 and PHKA1 with similar RNA-seq profiles and 
patterns of splicing sites in the ovarian cancer study formed a small cluster, where dotted vertical 
lines denote location of splicing sites.  
24 
 
B. Four genes CDCA2, TRAPPC11, PTPRG and ITGA10 with similar RNA-seq profiles and 
patterns of splicing sites  in the ovarian cancer study formed a small cluster, where dotted 
vertical lines denote location of splicing sites. 
 
Supplementary Note 1 
Two dimensional Functional Principal Component Analysis 
Consider a linear combination of functional values: 
 
S T
dsdttsxtsf ),(),( , 
where ),( ts  is a weight function and ),( tsx  is a centered random function. To capture the  
variations in the random functions, we chose weight function ),( ts  to maximize the variance of 
f .  By the formula for the variance of stochastic integral (1), we have  
221122221111 ).(),,,(),()var( tdsdtsdtststsRtsf
S T S T
      ,    (1) 
where )),(),,(cov(),,,( 22112211 tsxtsxtstsR  is the covariance function of the genetic variant 
function ),( tsx . Since multiplying )(t  by a constant will not change the maximizer of the 
variance )( fVar , we impose a constraint to make the solution unique: 
 1),(
2   dsdtts
T T
.                                                                             (2)  
Therefore, to find the weight function, we seek to solve the following optimization problem: 
.1),(
).(),,,(),(
2
221122221111


 
   
dsdtts
tdsdtsdtststsRts
T T
S T S T
          s.t.
        max
                                             (3)  
By the Lagrange multiplier, we reformulate the constrained optimization problem (3) into the 
following non-constrained optimization problem: 
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where  is a parameter.  
By variation calculus (2), we define the functional 
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which implies the following integral equation 
 ),().(),,,( 1122222211 tstdstststsR  
S T
                                         (5) 
for an appropriate eigenvalue  . The left side of the integral equation (5) defines a two 
dimensional  integral transform R of the weight function  . Therefore, the integral transform of 
the covariance function ),,,( 2211 tstsR is referred to as the covariance operator R . The integral 
equation (5) can be rewritten as 
  R ,                                                                                        (6) 
where ),,,( 2211 tsts  is an eigenfunction and referred to as a principal component function. 
Equation (6) is also referred to as a two dimensional eigenequation. Clearly, the eigenequation (6) 
looks the same as the eigenequation for the multivariate PCA if the covariance operator and 
eigenfunction are replaced by covariance matrix and eigenvector. 
Since the number of function values is theoretically infinity, we may have an infinite 
number of eigenvalues. Provided the functions iX and iY  are not linearly dependent, there will 
be only 1N  nonzero eigenvalues, where N is the total number of sampled individuals 
( GA nnN  ). Eigenfunctions satisfying the eigenequation are orthonormal (Ramsay and 
Silverman, 2005). In other words, equation (6) generates a set of principal component functions 
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These principal component functions satisfy 
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The principal component function 1 with the largest eigenvalue is referred to as the first 
principal component function, and the principal component function 2 with the second largest 
eigenvalue is referred to as the second principal component function, and continues. 
 
Computations for the Principal Component Function and the Principal Component Score 
The eigenfunction is an integral function and difficult to solve in closed form. A general 
strategy for solving the eigenfunction problem in (5) is to convert the continuous eigen-analysis 
problem to an appropriate discrete eigen-analysis task (Ramsay and Silverman 2005).  In this 
report, we use basis function expansion methods to achieve this conversion. 
     Let .2)}({ 2 jt jj  1-2j define j, each For functions. Fourier of series  thebe  We expand 
each genetic variant profile ),( tsxi as a linear combination of the basis function j : 
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where  denotes the Kronecker product of two matrices. 
Define the vector-valued function 
T
N tsxtsxtsX )],(,),,([),( 1  . The joint expansion of all N 
random functions can be expressed as 
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where the matrix C is given by 
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In matrix form we can express the variance-covariance function of the genetic variant profiles as  
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Similarly, the eigenfunction ),( ts can be expanded as 
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Substituting expansions (9) and (10) of variance-covariance ),,,( 2211 tstsR  and eigenfunction 
),( ts  into the functional eigenequation (5), we obtain 
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Since equation (11) must hold for all t, we obtain the following eigenequation: 
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Solving eigenequation (12), we obtain a set of orthonormal eigenvectors jb . A set of 
orthonormal eigenfunctions is given by 
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The random functions ),( tsxi can be expanded in terms of eigenfunctions as 
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Supplementary Note 2. 
Multivariate Functional Regression Models for Quantitative Trait Analysis  
      Assume that n individuals are sampled. Let Kkyik ,...,2,1,  be K trait values of the i -th 
individual.   Consider a genomic region ],[ ba   .    Let  )(txi  be a RNA-seq profile of the i-th 
individual defined in the region ],[ ba . Recall that a regression model for QTL analysis with the 
k -th trait and SNP data is defined as 

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1
1
J
j
ikkjijkik xy        (1) 
where k is an overall mean of the k -th trait, kj is the main genetic additive effect of the j -th 
SNP in the  genomic region for the k -th trait,  ijx is an indicator variable for the genotypes at the 
j -th SNP, Kkik ,..,1,   are independent and identically distributed normal variables with mean 
of zero and covariance matrix  .   
     Similar to the multiple regression models for QTL analysis with SNP data and multiple 
quantitative traits, the functional regression model for a quantitative trait can with RNA-seq data 
can be defined as 
,)()(0  
T
ikikkik dttxty                   (2)   
where k0 is an overall mean,  )(tk  are a genetic additive effect of a putative QTLs located at 
the genomic positions t for the k -th trait, Kk ,...,1  , )(txi  is a genotype profile, ik  are 
independent and identically distributed normal variables with mean of zero and covariance 
matrix  . 
Estimation of Additive Effects 
   We assume that both phenotypes and genotype profiles are centered. The genotype profiles 
 )(txi are expanded in terms of the orthonormal basis function as: 
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where )(tj are sequences of the orthonormal basis functions. The expansion coefficients ij  are 
estimated by  
 
T
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In practice, numerical methods for the integral will be used to calculate the expansion 
coefficients.  
Substituting equation (3) into equation (2), we obtain 
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where   
T
jkkj dttt )()( . The parameters kj are referred to as genetic additive  effect scores 
for the k -th trait. These scores can also be viewed as the expansion coefficients of the genetic 
effect functions with respect to orthonormal basis functions: 
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Then, equation (5) can be approximated by 
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         (7) 
The standard least square estimators of   and the variance covariance matrix    are given by 
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Denote the matrix 
TT  1)( by A . Then, the estimator of the parameter  is given by 
)(ˆ YYA  .        (10) 
The vector of the matrix  can be written as 
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By the assumption of the variance matrix of Y , we obtain the variance matrix of )(Yvec : 
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Thus, it follows from equations (11) and (12) that 
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Test Statistics 
 
An essential problem in QTL analysis or in integrative analysis of imaging and RNA-seq data is 
to test the association of  genomic region (or gene). Formally, we investigate the problem of 
testing the following hypothesis: 
,,...,1],,[,0)( Kkbattk  , 
which is equivalent to testing the hypothesis: 
0:0 H . 
Define the test statistic for testing the association of a genomic region with K  quantitative traits 
as 
  ˆˆ 1TT .                                                                                                          (14) 
Let )( rank r . 
Then, under the null hypothesis  0:0 H , T is asymptotically distributed as a central 
2
)(KJ or 
2
)(r distribution if J components are taken in the expansion equation (3). 
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Table 1. P-values of three statistics for testing association of 
expression with images in ovarian cancer study. 
Gene P-value 
 
MFLM_FPC MFLM_Descriptor MLM 
ZNF805 2.31E-10 4.34E-01 9.33E-01 
LOC653501 3.86E-09 2.49E-02 9.04E-01 
TMEM170B 1.23E-08 6.18E-03 9.11E-01 
DRP2 2.38E-08 9.76E-02 5.89E-01 
OR6V1 5.27E-08 2.07E-03 1.76E-01 
GPR113 7.09E-08 3.67E-07 5.70E-01 
ZNF484 4.47E-07 6.77E-03 9.34E-01 
DNAL1 7.00E-07 6.64E-03 8.59E-01 
ITGA10 8.72E-07 2.01E-01 6.41E-01 
NBEAL1 9.43E-07 7.67E-03 7.12E-01 
C16orf52 1.13E-06 2.10E-02 9.06E-01 
PHKA1 1.31E-06 2.80E-02 7.15E-01 
PTPRG 1.39E-06 9.50E-01 6.58E-01 
IFT88 1.64E-06 1.09E-05 8.11E-01 
PARD3B 1.78E-06 8.89E-01 4.49E-01 
LIMD1 2.11E-06 4.69E-01 8.71E-01 
FAM73A 2.13E-06 3.97E-03 9.28E-01 
CAPN14 2.45E-06 1.78E-02 4.80E-01 
CPEB3 2.55E-06 2.62E-02 9.88E-01 
CDCA2 2.80E-06 9.73E-01 3.74E-01 
PUS3 3.08E-06 7.81E-01 9.22E-01 
 
Table 2.  P-values of three statistics for testing association of expression with images in KIRC study. 
Gene P-value Gene P-value 
 MFLM (FPC) MFLM (Descriptor) MLM  MFLM(FPC) MFLM(Descriptor) MLM 
HELZ 6.62E-16 6.08E-01 8.79E-01 ZNF81 9.95E-08 2.06E-07 7.25E-01 
MARCH9 2.12E-15 1.02E-06 7.58E-01 GAB2 1.04E-07 1.34E-02 6.38E-01 
MSH5-SAPCD1 8.98E-13 9.79E-03 NA
*
 MMP24-AS1 1.29E-07 3.26E-06 NA 
SLC2A12 2.52E-12 9.94E-03 2.76E-08 LOC647859 1.43E-07 8.56E-02 1.23E-03 
BRWD1 1.26E-11 5.61E-03 9.54E-01 C2orf68 1.49E-07 4.83E-03 7.84E-01 
RFX7 5.29E-11 1.00E+00 9.58E-01 SDR39U1 1.57E-07 8.83E-04 5.88E-01 
C22orf39 6.55E-11 1.29E-03 5.77E-01 ZRANB3 1.66E-07 1.03E-03 9.59E-01 
NSD1 7.06E-11 1.67E-02 9.74E-01 PSMC4 1.71E-07 1.39E-02 8.87E-01 
RTF1 1.82E-10 9.49E-01 8.58E-01 FLJ12825 1.74E-07 1.39E-04 7.08E-01 
MBD5 3.00E-10 1.08E-04 9.33E-01 ARHGEF11 2.26E-07 8.24E-03 8.55E-01 
ZSCAN16-AS1 4.16E-10 6.08E-02 NA LOC100289019 2.61E-07 8.50E-04 NA 
SESN1 4.84E-10 3.42E-01 6.71E-01 SUFU 2.79E-07 1.99E-01 5.84E-01 
ITGA9 5.12E-10 2.11E-02 9.52E-01 ZNF555 3.75E-07 2.16E-02 3.75E-01 
PPM1K 5.60E-10 1.48E-01 1.11E-04 KHNYN 3.85E-07 1.54E-01 4.62E-01 
USP42 1.39E-09 9.79E-01 9.06E-01 ANKRD11 4.80E-07 1.00E+00 8.92E-01 
FAM47E-STBD1 1.77E-09 1.11E-02 NA BOLA2 4.82E-07 9.88E-02 8.33E-01 
ZNF710 2.05E-09 1.22E-01 9.82E-01 BOLA2B 4.82E-07 9.88E-02 NA 
TECPR2 3.59E-09 9.53E-04 5.63E-01 SAPCD1 4.97E-07 4.24E-01 NA 
RASSF8-AS1 3.88E-09 3.08E-03 NA SLC9A4 6.26E-07 2.27E-02 1.87E-01 
CCDC93 4.04E-09 1.00E+00 9.45E-01 CRYBG3 6.30E-07 5.18E-03 5.59E-02 
NAV2 4.90E-09 4.11E-02 1.17E-01 SLC15A2 6.78E-07 1.18E-04 3.63E-05 
CYB5B 6.75E-09 5.52E-04 7.11E-01 BRD4 7.77E-07 5.46E-01 9.85E-01 
ANKRD17 7.55E-09 1.00E+00 4.47E-01 ATP6V1C2 7.80E-07 2.86E-03 1.88E-01 
CCDC181 7.98E-09 5.24E-03 NA SMAD2 9.23E-07 9.38E-01 7.52E-01 
SPHK2 1.08E-08 3.26E-03 1.83E-02 ST3GAL6 1.19E-06 5.01E-01 2.16E-01 
KCNN3 1.15E-08 9.47E-01 9.17E-01 ZMIZ1 1.26E-06 3.75E-01 9.46E-01 
ZFYVE16 1.16E-08 1.98E-02 7.65E-01 USP34 1.36E-06 1.74E-03 8.24E-01 
CMTM1 1.23E-08 9.99E-01 3.66E-01 RALGAPA2 1.38E-06 3.48E-03 1.57E-01 
LINC00875 1.69E-08 1.00E+00 NA FRMD4A 2.03E-06 5.14E-03 7.95E-01 
NOTCH1 1.81E-08 1.96E-02 1.80E-01 PSMA5 2.12E-06 7.81E-02 9.35E-01 
BLZF1 1.87E-08 2.05E-03 8.94E-01 RIPPLY1 2.18E-06 1.00E+00 3.89E-06 
CHD2 3.55E-08 1.28E-01 9.47E-01 ERCC6 2.20E-06 1.21E-01 7.01E-01 
MTUS1 4.71E-08 8.63E-02 2.18E-01 MINK1 2.29E-06 1.19E-02 9.14E-01 
REV3L 4.96E-08 2.28E-02 9.59E-01 DIP2C 2.38E-06 2.51E-03 9.13E-01 
LRIG2 5.00E-08 6.78E-03 8.40E-01 PHLDB2 2.51E-06 3.45E-03 6.34E-01 
DENND1C 5.83E-08 9.41E-01 2.40E-01 TBC1D24 2.54E-06 7.79E-01 2.13E-01 
TMEM50B 6.77E-08 4.16E-03 8.31E-02 APBA3 2.55E-06 7.20E-02 1.29E-01 
CELF1 7.92E-08 1.00E+00 9.13E-01 TRAK1 2.60E-06 7.67E-01 1.53E-01 
ZSCAN20 8.41E-08 1.23E-06 9.37E-01 DLC1 2.60E-06 7.23E-02 8.35E-01 
MINA 8.76E-08 1.61E-03 4.43E-03 NISCH 2.62E-06 1.00E+00 2.28E-01 
C5AR2 9.01E-08 4.97E-02 NA CPEB3 2.64E-06 9.82E-01 4.91E-03 
SSH2 9.68E-08 1.00E-02 3.00E-01 UFD1L 2.94E-06 3.03E-03 7.78E-01 
 
                                                          
*
 NA: Expression (level 3) data were not available. 
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Table S1. P-values of the test for association of gene expressions with imaging and differential 
expressions between tumor and normal tissue samples in the KIRC study. 
Gene P-values Gene P-values 
 
MFLM_FPC 
Differential 
Expression  
MFLM_FPC 
Differential 
Expression 
HELZ 6.62E-16 8.65E-08 ZNF81 9.95E-08 NA 
MARCH9 2.12E-15 NA GAB2 1.04E-07 9.16E-06 
MSH5.SAPCD1 8.98E-13 7.13E-12 MMP24.AS1 1.29E-07 6.58E-01 
SLC2A12 2.52E-12 <1.0 E-27 LOC647859 1.43E-07 3.00E-02 
BRWD1 1.26E-11 9.17E-08 C2orf68 1.49E-07 3.27E-06 
RFX7 5.29E-11 1.48E-01 SDR39U1 1.57E-07 6.66E-16 
C22orf39 6.55E-11 2.52E-11 ZRANB3 1.66E-07 NA 
NSD1 7.06E-11 4.44E-16 PSMC4 1.71E-07 5.11E-11 
RTF1 1.82E-10 <1.0 E-27 FLJ12825 1.74E-07 NA 
MBD5 3.00E-10 3.47E-13 ARHGEF11 2.26E-07 6.50E-02 
ZSCAN16.AS1 4.16E-10 NA LOC100289019 2.61E-07 9.86E-02 
SESN1 4.84E-10 4.22E-02 SUFU 2.79E-07 4.45E-07 
ITGA9 5.12E-10 4.13E-08 ZNF555 3.75E-07 NA 
PPM1K 5.60E-10 1.11E-16 KHNYN 3.85E-07 2.44E-01 
USP42 1.39E-09 NA ANKRD11 4.80E-07 7.49E-06 
FAM47E.STBD1 1.77E-09 1.54E-02 BOLA2B 4.82E-07 4.65E-06 
ZNF710 2.05E-09 NA BOLA2 4.82E-07 6.96E-06 
TECPR2 3.59E-09 2.38E-11 SAPCD1 4.97E-07 6.51E-09 
RASSF8.AS1 3.88E-09 7.97E-01 SLC9A4 6.26E-07 NA 
CCDC93 4.04E-09 4.13E-03 CRYBG3 6.30E-07 1.58E-06 
NAV2 4.90E-09 3.51E-01 SLC15A2 6.78E-07 8.05E-11 
CYB5B 6.75E-09 2.25E-08 BRD4 7.77E-07 8.09E-04 
ANKRD17 7.55E-09 8.11E-03 ATP6V1C2 7.80E-07 1.05E-07 
CCDC181 7.98E-09 NA SMAD2 9.23E-07 5.33E-05 
SPHK2 1.08E-08 3.84E-07 ST3GAL6 1.19E-06 1.53E-08 
KCNN3 1.15E-08 1.57E-04 ZMIZ1 1.26E-06 NA 
ZFYVE16 1.16E-08 NA USP34 1.36E-06 NA 
CMTM1 1.23E-08 2.64E-03 RALGAPA2 1.38E-06 7.06E-13 
LINC00875 1.69E-08 7.54E-04 FRMD4A 2.03E-06 0.00E+00 
NOTCH1 1.81E-08 3.71E-02 PSMA5 2.12E-06 1.95E-03 
BLZF1 1.87E-08 4.03E-12 RIPPLY1 2.18E-06 NA 
CHD2 3.55E-08 2.57E-08 ERCC6 2.20E-06 0.00E+00 
MTUS1 4.71E-08 9.48E-11 MINK1 2.29E-06 0.00E+00 
REV3L 4.96E-08 2.12E-03 DIP2C 2.38E-06 1.32E-14 
LRIG2 5.00E-08 1.25E-13 PHLDB2 2.51E-06 6.66E-16 
DENND1C 5.83E-08 1.20E-02 TBC1D24 2.54E-06 8.88E-01 
TMEM50B 6.77E-08 1.08E-05 APBA3 2.55E-06 5.83E-14 
CELF1 7.92E-08 3.99E-10 DLC1 2.60E-06 2.20E-04 
ZSCAN20 8.41E-08 NA TRAK1 2.60E-06 5.01E-02 
MINA 8.76E-08 < 1.0 E-27 NISCH 2.62E-06 1.03E-01 
C5AR2 9.01E-08 <1.0 E-27 CPEB3 2.64E-06 5.64E-01 
SSH2 9.68E-08 3.85E-01 UFD1L 2.94E-06 NA 
NA: Test for differential expression was not conducted due to technique problems. 
